SCHEMBL1677111

SCHEMBL1677111

CS(=O)(=O)c1ccc(Oc2ccc(N)c(OCc3ccccc3)c2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
GHSR Q92847 1/20 0.42
CYP19A1 P11511 3/20 0.40
IKBKB O14920 1/20 0.39
ADAMTS4 O75173 1/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP13 P45452 1/20 0.39
MMP14 P50281 1/20 0.39
ADAMTS5 Q9UNA0 1/20 0.39
PTGER1 P34995 3/20 0.39
ACACB O00763 3/20 0.38
ACACA Q13085 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL563591 0.86 CA12 (0.48) CA12CA1CA2CA4CA5A
SCHEMBL1039049 0.84 POLB (0.44) CYP19A1ALDH1A1HTTNPSR1NPC1
SCHEMBL12734151 0.83 LIPE (0.41) ACACBACACAOPRM1ALDH1A1HTT
SCHEMBL1677309 0.80 CYP19A1 (0.41) CA12CA1CA2CA4CA5A
SCHEMBL1677263 0.80 ALDH1A1 (0.43) ACACBPTGS1PTGS2ALDH1A1
SCHEMBL1677258 0.79 MMP2 (0.44) ADAMTS4MMP1MMP2MMP13MMP14
SCHEMBL10833881 0.76 ADAMTS4 (0.53) ADAMTS4MMP1MMP2MMP13MMP14
SCHEMBL12327379 0.75 ADAMTS4 (0.56) ADAMTS4MMP1MMP2MMP13MMP14
SCHEMBL30058080 0.74 MAOB (0.50) PTGS1PTGS2RAB9ASMN1; SMN2
SCHEMBL647614 0.74 MAOB (0.50) PTGS1PTGS2RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673942-B2 Fused ring compounds and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-18 US disclosed
US-8673942-B2 Fused ring compounds and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-18 US disclosed
US-20110098297-A1 FUSED RING COMPOUNDS AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-04-28 US disclosed
US-20110098297-A1 FUSED RING COMPOUNDS AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-04-28 US disclosed
WO-2009125873-A1 FUSED RING COMPOUNDS AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098297-A1 FUSED RING COMPOUNDS AND USE THEREOF GCKR, GPR119, SLC5A1 CA12 2531/4885CA1 1959/4885CA2 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.